Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode. [Operator ...

In recent trading, Lexicon Pharmaceuticals Inc (LXRX) stock price has shown some volatility, fluctuating -33.33% over the last five trades and -22.62% over the past 30 trades. This represents a ...

Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital ...

Independent advisers to the FDA voted against recommending Lexicon Pharmaceuticals‘ add-on treatment to insulin therapy for ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.44% of ...

The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and chronic kidney disease.

A simultaneous webcast will be available in the “Events” section of the Lexicon website at and a recording of the webcast will be available for two weeks following the original on-demand date. About ...

Pharmaceuticals announced it will present data from two studies related to LX9851, its investigational compound for obesity and ...

with a majority of members saying the data provided by sponsor Lexicon Pharmaceuticals contained too much uncertainty. "I ...

Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic ...

An FDA advisory committee voted Thursday that it didn’t believe the benefits of Lexicon's (LXRX) diabetes drug sotagliflozin ...

Lexicon Pharmaceuticals' sotagliflozin, under review as an adjunct to insulin for type 1 diabetes and CKD, faced an FDA panel vote against approval, with mixed expert support.